CagriSema
Also known as: cagrilintide + semaglutide
Profile at a glance
| Attribute | Value |
|---|---|
| Sponsor | Novo Nordisk |
| Mechanism | GLP-1 + amylin (fixed-dose combination) |
| Administration | Once-weekly subcutaneous injection |
| Peak weight loss | ~20.4% at 68 weeks (REDEFINE 1) |
| Status | NDA filed December 2025 — regulatory decision expected 2026 |
Deep dive
What Is CagriSema? Novo Nordisk's Amylin + GLP-1 Weight Loss Combination →Novo Nordisk's amylin + GLP-1 combination — 20.4% weight loss in REDEFINE 1, NDA filed December 2025.
CagriSema compared
Every head-to-head we've published involving CagriSema.
Retatrutide vs CagriSema (Cagrilintide + Semaglutide): Triple Agonist vs Amylin + GLP-1 Combo
Cagrilintide vs retatrutide: triple agonist vs amylin + GLP-1 combo — 28.7% vs 22.7% weight loss, different receptors, and stacking considerations.
Updated February 2026
CagriSema vs Tirzepatide (Zepbound): REDEFINE 4 Head-to-Head Results
CagriSema lost to tirzepatide in REDEFINE 4: 23.0% vs 25.5% weight loss at 84 weeks. Retatrutide achieved 28.7% in TRIUMPH-4.
Updated February 2026
Cagrilintide and Tirzepatide: Stacking Amylin With a Dual Agonist
Cagrilintide + tirzepatide stacking: no human trial data, CagriSema lost to tirzepatide in REDEFINE 4, and retatrutide offers 28.7% weight loss from one molecule.
Updated February 2026
Related articles
Safety, mechanism, and context pieces that reference CagriSema.
What Is Cagrilintide? The Amylin Analog Behind CagriSema
Novo Nordisk's long-acting amylin analog — 11.5% weight loss as monotherapy, and the key ingredient in CagriSema.
Updated February 2026
Dave Nap on CagriSema vs Tirzepatide, Novo Nordisk's Triple Agonist UBT-251, and Retatrutide: Fact Check
On The Pen host Dave Nap on CagriSema vs tirzepatide, Novo Nordisk triple agonist UBT-251, and retatrutide — fact-checked.
Updated February 2026
See all drug profiles in the drug profiles hub or compare drugs head-to-head in the comparisons hub.